my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
10-14-2010: Bayer Schering Pharma AG, Germany, has successfully concluded the European registration procedure for the introduction of Qlaira in the new indication treatment of heavy menstrual bleeding in women without organic pathology who desire oral contraception. The Netherlands served as Reference Member State for the decentralized procedure to gain Europe-wide Marketing Authorization for the new indication. Qlaira is the first in a new class of oral contraceptives to deliver estradiol, the same estrogen as the one produced by the female body. In addition, it also contains dienogest, a progestogen which is well-investigated. It has a unique dosing regimen which has been designed to deliver hormones at the right levels at the right time during the cycle. Qlaira is already marketed in over 25 European countries as an oral contraceptive.
Contact / Request information
Request further information free of charge:
Watchlist
This is where you can add this news to your personal favourites
Dr. Dirk Ehle appointed Head of Bayer HealthCare's Animal Health Division
Dr. Dirk Ehle has been appointed Head of the Animal Health Division of Bayer HealthCare AG effective May 1, 2012. The 42-year-old succeeds Dr. Jean-Luc Lowinski, who is leaving the company at his own request. As divisional head, Ehle will also be member of the Bayer HealthCare Executive Com ... more
Encouraging start to the year for Bayer
The Bayer Group saw a successful start to 2012. “All the subgroups contributed to the encouraging increase in sales, particularly CropScience, which experienced a strong start to the season,” Management Board Chairman Dr. Marijn Dekkers explained on Thursday when the first-quarter interim r ... more
Bayer sets ambitious targets for 2014
The Bayer Group sees good perspectives for its businesses in the medium term. “In the life science areas – HealthCare and CropScience – we anticipate further increases in sales and margins through 2014,” said CEO Dr. Marijn Dekkers at the “Meet Management” investor conference on Wednesday i ... more
BAYER INNOVATION GmbH (BIG) is part of Bayer’s innovation strategy and complements the innovation activities of the different subgroups in the fields of health care, nutrition and high-quality materials. Objective of BIG is to identify and develop new growth opportunities, thus preparing ... more
Bayer is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Our products and services are designed to benefit people and improve their quality of life. At the same time we want to create value through innovation, growth and high earni ... more
Bayer Pharmaceuticals Corporation
Outstanding specialty care takes constant innovation and dedication. These core values set Bayer HealthCare Pharmaceuticals apart and enable us to offer an industry-leading portfolio of products and support that healthcare providers and their patients require. Bayer HealthCare Pharmaceutic ... more
Partnering with community leaders and providing philanthropic support have long been a part of Bayer Corporation's culture. In 1953, Bayer created the first of three foundations that later all merged to become the Bayer Foundation. The Bayer Foundation is an endowed 501(c)(3) entity and is ... more
The Lead Discovery Center GmbH (LDC), based in Dortmund, Germany, a spin-off from Max-Planck-Innovation GmbH (MI) in Munich, with expertise in small molecule pharmaceutical drug discovery, has successfully licensed its first lead structure to a pharma partner. The agreement grants Bayer Sch ... more
EU regulators okay Qlaira for the treatment of heavy menstrual bleeding
Bayer Schering Pharma AG, Germany, has successfully concluded the European registration procedure for the introduction of Qlaira in the new indication treatment of heavy menstrual bleeding in women without organic pathology who desire oral contraception. The Netherlands served as Reference ... more
Bayer launches Betaferon in China
Bayer Schering Pharma announced the upcoming launch in China of Betaferon® (interferon beta-1b) for the treatment of relapsing-remitting forms of multiple sclerosis (MS). Betaferon is already approved in over 100 countries worldwide. With Betaferon and Gadovist®1.0, which was also recently ... more
Bayer Schering Pharma’s goal is a leading market position in each of its specialist fields. With its distinctive expertise, the company engages in research on new drugs which, as innovative therapies, make an essential contribution toward improving people’s quality of life. Our outstanding ... more
Bayer is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Our products and services are designed to benefit people and improve their quality of life. At the same time we want to create value through innovation, growth and high earni ... more
Bayer Schering Pharma’s goal is a leading market position in each of its specialist fields. With its distinctive expertise, the company engages in research on new drugs which, as innovative therapies, make an essential contribution toward improving people’s quality of life. Our outstanding ... more
About CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2012 CHEMIE.DE Information Service GmbH, All rights reserved
